Hideo Yagita Selected Research

TNF-Related Apoptosis-Inducing Ligand

1/2021	Epigenetic Modification of Death Receptor Genes for TRAIL and TRAIL Resistance in Childhood B-Cell Precursor Acute Lymphoblastic Leukemia.
9/2013	Berberine enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast cancer.
12/2012	c-FLIP maintains tissue homeostasis by preventing apoptosis and programmed necrosis.
12/2011	Importin β1 protein-mediated nuclear localization of death receptor 5 (DR5) limits DR5/tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced cell death of human tumor cells.
7/2010	Optimized combination therapy using bortezomib, TRAIL and TLR agonists in established breast tumors.
11/2008	CD4+CD25+ Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer.
6/2006	Eradication of established tumors in mice by a combination antibody-based therapy.
2/2006	TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer.
10/2005	TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice.
3/2005	TRAIL identifies immature natural killer cells in newborn mice and adult mouse liver.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideo Yagita Research Topics

Disease

150	Neoplasms (Cancer) 10/2022 - 01/2002
31	Inflammation (Inflammations) 01/2021 - 01/2004
24	Infections 01/2017 - 06/2003
20	Neoplasm Metastasis (Metastasis) 01/2021 - 02/2002
15	Colitis 01/2021 - 02/2003
15	Autoimmune Diseases (Autoimmune Disease) 01/2019 - 07/2002
14	Melanoma (Melanoma, Malignant) 11/2021 - 04/2008
14	Breast Neoplasms (Breast Cancer) 01/2021 - 12/2005
13	Necrosis 10/2018 - 01/2002
12	Graft vs Host Disease (Graft-Versus-Host Disease) 02/2016 - 07/2002
9	Allergic Conjunctivitis (Giant Papillary Conjunctivitis) 11/2014 - 10/2004
8	Reperfusion Injury 01/2021 - 08/2008
8	Asthma (Bronchial Asthma) 01/2017 - 04/2003
7	Atherosclerosis 01/2019 - 01/2007
7	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2019 - 07/2003
6	Ischemia 01/2021 - 08/2008
6	Leukemia 01/2021 - 05/2003
6	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2019 - 05/2002
6	Lymphoma (Lymphomas) 01/2016 - 10/2002
6	Eosinophilia 07/2011 - 07/2003
5	Hypersensitivity (Allergy) 10/2022 - 07/2003
5	Arthritis (Polyarthritis) 01/2018 - 10/2002
5	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 03/2015 - 10/2003
5	Experimental Arthritis 11/2014 - 10/2002
5	Contact Dermatitis (Eczema, Contact) 11/2014 - 10/2003
5	Multiple Sclerosis 03/2014 - 03/2010
5	Fibrosis (Cirrhosis) 01/2013 - 05/2004
5	Chagas Disease (American Trypanosomiasis) 04/2007 - 04/2002
4	Glomerulonephritis 01/2021 - 02/2006
4	Carcinoma (Carcinomatosis) 12/2020 - 09/2004
4	Sepsis (Septicemia) 01/2020 - 09/2009
4	Colonic Neoplasms (Colon Cancer) 01/2020 - 09/2004
4	Rheumatoid Arthritis 01/2018 - 10/2002
4	Lupus Nephritis 05/2014 - 03/2002
4	Demyelinating Diseases (Demyelinating Disease) 03/2014 - 03/2010
4	Carcinogenesis 01/2014 - 04/2009
4	Hepatitis 01/2013 - 10/2004
4	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011 - 04/2007
3	Esophageal Neoplasms (Esophageal Cancer) 11/2021 - 04/2005
3	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2021 - 10/2010

Drug/Important Bio-Agent (IBA)

72	LigandsIBA 01/2021 - 01/2002
47	Monoclonal AntibodiesIBA 01/2022 - 01/2002
45	CytokinesIBA 01/2021 - 02/2002
45	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 01/2002
34	AntigensIBA 01/2022 - 05/2002
26	AntibodiesIBA 01/2021 - 01/2003
19	Proteins (Proteins, Gene)FDA Link 01/2020 - 10/2002
16	TNF-Related Apoptosis-Inducing LigandIBA 01/2021 - 02/2002
15	Fas Ligand Protein (Fas Ligand)IBA 01/2017 - 02/2002
13	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 11/2013 - 02/2004
12	VaccinesIBA 01/2021 - 08/2008
12	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 06/2003
11	Interleukin-10 (Interleukin 10)IBA 01/2020 - 10/2003
10	Therapeutic UsesIBA 01/2022 - 09/2003
9	PerforinIBA 01/2018 - 01/2002
9	Interleukin-2 (IL2)IBA 01/2017 - 10/2003
9	Messenger RNA (mRNA)IBA 04/2016 - 03/2002
9	Immunoglobulins (Immunoglobulin)IBA 05/2014 - 04/2010
8	Immune Checkpoint InhibitorsIBA 01/2022 - 01/2017
8	Death Domain ReceptorsIBA 01/2021 - 01/2003
8	InterferonsIBA 10/2019 - 01/2002
8	Peptides (Polypeptides)IBA 01/2019 - 12/2004
8	Immunoglobulin G (IgG)IBA 10/2017 - 10/2002
7	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2022 - 12/2004
7	NF-kappa B (NF-kB)IBA 01/2020 - 09/2003
7	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2019 - 11/2009
7	Neutralizing AntibodiesIBA 10/2017 - 10/2004
7	alpha-galactosylceramideIBA 08/2007 - 02/2002
6	EpitopesIBA 01/2017 - 10/2004
6	MucinsIBA 12/2013 - 02/2007
6	Interleukin-4 (Interleukin 4)IBA 03/2013 - 02/2002
6	Interferon-gamma (Interferon, gamma)IBA 02/2012 - 01/2002
5	AllergensIBA 01/2021 - 04/2003
5	Interleukin-6 (Interleukin 6)IBA 01/2021 - 01/2013
5	ChemokinesIBA 10/2020 - 01/2011
5	Pharmaceutical PreparationsIBA 01/2020 - 03/2003
5	Immunoglobulin E (IgE)IBA 03/2017 - 10/2003
5	Interleukin-12 (IL 12)IBA 11/2016 - 02/2002
5	B7-H1 AntigenIBA 04/2016 - 03/2006
5	CaspasesIBA 01/2016 - 01/2002
5	TWEAK ReceptorIBA 07/2013 - 01/2002
5	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 04/2013 - 09/2003
5	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 12/2012 - 07/2007
4	Neoplasm Antigens (Tumor Antigens)IBA 01/2022 - 03/2009
4	InterleukinsIBA 01/2021 - 05/2007
4	Programmed Cell Death 1 ReceptorIBA 01/2020 - 02/2006
4	EnzymesIBA 01/2019 - 01/2003
4	IntegrinsIBA 01/2019 - 09/2013
4	interleukin-21 (interleukin 21)IBA 11/2014 - 06/2005
4	OvalbuminIBA 11/2014 - 04/2003
4	Mucin-1 (CA 15-3 Antigen)IBA 05/2014 - 02/2008
4	Interleukin-18 (Interleukin 18)IBA 06/2012 - 02/2002
4	CarcinogensIBA 05/2011 - 01/2002
3	Biological ProductsIBA 01/2021 - 08/2009
3	Blocking AntibodiesIBA 01/2021 - 06/2003

Therapy/Procedure

60	Therapeutics 01/2022 - 11/2002
51	Immunotherapy 10/2022 - 04/2002
11	Drug Therapy (Chemotherapy) 01/2020 - 01/2006
9	Ligation 01/2020 - 05/2003
5	Radiotherapy 01/2017 - 07/2012